Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Aug 10;12(1):13592.
doi: 10.1038/s41598-022-17743-6.

Neoadjuvant chemotherapy or upfront surgery in localized pancreatic cancer: a contemporary analysis

Pedro Luiz Serrano Uson Junior  1   2 , Leonardo Carvalho  3   4 , Milena Lourenço Coleta Fernandes  3   4 , Gehan Botrus  5 , Rodrigo de Souza Martins  3   4 , Elaine Ferreira da Silva  3   4 , Sarah Silva Mello Batista Dos Santos  3   4 , Leticia Taniwaki  3   4 , Patrícia Taranto  3   4 , Ana Carolina Pereira Dutra  3   4 , João Bosco de Oliveira Filho  3   4 , Sergio Eduardo Alonso Araujo  3   4 , Fernando Moura  3   4
Affiliations

Neoadjuvant chemotherapy or upfront surgery in localized pancreatic cancer: a contemporary analysis

Pedro Luiz Serrano Uson Junior et al. Sci Rep. .

Abstract

Neoadjuvant chemotherapy is considered a new treatment option for potentially resectable pancreatic cancer. However, data are not well established on overall survival and delaying surgery in resectable pancreatic cancer, as well as on those patients that ultimately cannot undergo surgery. We analyzed pancreatic cancer patients treated in a tertiary hospital from January 2016 to December 2020. Patients with resectable stage I and II pancreatic cancer were evaluated regarding surgery, neoadjuvant treatment, and other clinical demographics. The survival function was estimated using the Kaplan-Meier method, and the relationship between the variables of interest and the overall survival (OS) was assessed by adopting the proportional regression Cox models. A total of 216 patients were evaluated. 81 of them with resectable/borderline resectable disease and 135 with unresectable /metastatic disease at diagnosis. Median OS for stage I and II disease were 36 and 28 months, respectively. For resectable pancreatic cancer median OS was 28 months, for borderline resectable pancreatic cancer median OS was 11 months. Median OS for stage III (locally advanced) and stage IV (metastatic) were 10 and 7 months, respectively (p < 0.0001). Median OS of 9 months were obtained for patients with stage I and II that did not undergo surgery compared to 25 months in patients that underwent surgery in any time (p < 0.001). Comparing patients with localized disease, median OS for patients treated with upfront surgery was 28 months, compared to 15 months in patients treated with neoadjuvant approach (p = 0.04). Most patients that did not undergo surgery have decline of performance status or disease progression on neoadjuvant treatment. On multivariable analysis in pancreatic cancer stages I and II, including age, sex, borderline or resectable disease, CA 19-9, positive lymph nodes and neoadjuvant treatment, the surgery was the only factor associated with improved overall survival (p = 0.04). Upfront surgery should still be considered a standard of care approach for resectable pancreatic cancer. Biomarker driven studies and randomized trials with combination therapies are necessary to address neoadjuvant chemotherapy and delaying surgery in purely resectable pancreatic cancer.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Figure 1
Figure 1
Survival rates by staging.
Figure 2
Figure 2
Survival rates by resectability.
Figure 3
Figure 3
Overall survival in upfront surgery versus neoadjuvant treatment.
See this image and copyright information in PMC

References

    1. Siegel, Rebecca, L., et al. Cancer statistics, 2021. CA Cancer J. Clin.71(1), 7–33 (2021). - PubMed
    1. Usón, P. L. S., et al. The impact of metastatic sites in advanced pancreatic adenocarcinoma, systematic review and meta-analysis of prospective randomized studies. PloS One15(3), e0230060 (2020). - PMC - PubMed
    1. Conroy, T., et al. FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. N. Engl. J. Med.379(25), 2395–2406 (2018). - PubMed
    1. Versteijne E, et al. Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer: Results of the Dutch randomized phase III PREOPANC trial. J. Clin. Oncol. 2020;38(16):1763. doi: 10.1200/JCO.19.02274. - DOI - PMC - PubMed
    1. Versteijne, E., et al. Neoadjuvant chemoradiotherapy versus upfront surgery for resectable and borderline resectable pancreatic cancer: Long-term results of the Dutch randomized PREOPANC trial. J. Clin. Oncol. JCO-21 (2022). - PubMed

MeSH terms